NRIX - nurixtx.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Nurix Therapeutics (NRIX)

Nurix Therapeutics (NRIX) utilizes an asset-light model by outsourcing drug manufacturing to third-party contractors. The company develops oral agents designed to eliminate pathogenic structures via protein degradation. The scaling of clinical programs is supported by partnerships with biopharmaceutical behemoths. The value of 0.00 describes the current valuation level, which is clearly demonstrated by the historical P/E to growth trend.

NRIX: nurixtx.com Price/Earnings to Growth Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Nurix Therapeutics (NRIX)

- market value and analyst target forecast:
Price Rate Chart Nurix Therapeutics Inc|NRIX - Consensus Target
- market capitalization statistics:
Market Value Nurix Pharma|NRIX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Nurix Therapeutics|NRIX - Company Net Assets|Market Cap to Book Value Multiple nurixtx.com|NRIX - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Nurix Therapeutics|NRIX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital nurixtx.com|NRIX - Company Aggregate Debts|Debt to Net Assets Nurix Pharma|NRIX - Company Long-Term Debts|Short-Term Debt Nurix Therapeutics|Intermediate Liquidity Ratio nurixtx.com
- earnings and valuation multiples information:
NRIX - Net Profit|Expected Net Profit Nurix Therapeutics|NRIX - P/E Multiple|Price to Future Earnings Ratio Nurix Corp|NRIX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Nurix Pharma|NRIX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Nurix Therapeutics|NRIX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months nurixtx.com|NRIX - Earnings growth in current year|Expected net earnings per share growth next year Nurix Therapeutics
- sales revenue and business income indicators:
NRIX - Company Revenue|Company Future Revenue Nurix Therapeutics Inc|NRIX - P/S Multiple|Forward P/S Multiple Nurix Pharma
General company analysis:Nurix Therapeutics
Signature product of nurixtx.com

The PEG ratio relates the market value of earnings to their growth rate, where a value below one signals that an asset is undervalued relative to business expansion. By analyzing the correlation between P/E and growth rates, an investor can identify "rocket" potential, which is particularly relevant for Nurix Therapeutics (NRIX) as it scales clinical trials and penetrates the untapped targeted protein degradation market.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Exelixis Corp - Price/Earnings to Growth Multiple|Nuvalent Therapeutics (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Pharma) - PEG Multiple|PEG Multiple Tyra Corp|Price/Earnings to Growth Ratio Verastem, Inc. (VSTM)|GLUE (monterosatx.com) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Therapeutics, Inc.)|Price to Net Income Growth Ratio Immuneering Corp|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio